————————————————————
For an estimated 3 to 8 percent of menstruating people in the US, the days before each period bring not just irritability or bloating but disabling depression, anxiety, anger, or panic that lifts within days of bleeding starting. PMDD — premenstrual dysphoric disorder — is now recognized as a distinct mood disorder, validating what many people had described for years: that a small fraction of premenstrual symptom syndromes are far more severe than ordinary PMS and warrant targeted, clinician-directed treatment. It was first listed as a full diagnosis in the DSM-5 in 2013, and the diagnostic criteria were carried forward and refined in the DSM-5-TR (the text revision published by the American Psychiatric Association in 2022).
This article is educational and is not medical advice. PMDD is a serious condition, and the right diagnosis and treatment can only be worked out with a qualified clinician. If you recognize yourself in what follows, please treat it as a prompt to seek an evaluation — not as a manual for self-treatment.
What PMDD Is and How Common It Is
PMDD is a cyclic mood disorder in which severe affective and physical symptoms occur during the luteal phase of the menstrual cycle (roughly the week or two before menstruation), remit within a few days of menses onset, and are largely absent during the postmenstrual week. The DSM-5-TR requires that symptoms be present during most cycles in the past year, that they be confirmed by prospective symptom tracking over at least two cycles, and that they cause significant distress or interference with work, school, relationships, or social functioning.
According to the American College of Obstetricians and Gynecologists (ACOG), PMDD affects approximately 3 to 8 percent of menstruating people — although population studies using strict prospective criteria have reported a somewhat lower range (often cited as around 1.3 to 5.8 percent). Either way, PMDD is distinct from, and far less common than, the much larger group with milder premenstrual syndrome. Onset typically occurs in the late teens or 20s, and symptoms often worsen in perimenopause before resolving with menopause. For broader context on cyclical mood disorders, see our medical conditions resource.
Causes
The exact cause of PMDD is not fully understood. Current evidence points to an abnormal sensitivity to normal hormonal fluctuations rather than to abnormal hormone levels themselves. Allopregnanolone, a metabolite of progesterone that interacts with GABA-A receptors, appears to behave differently in people with PMDD, which may contribute to anxiety and mood symptoms during the luteal phase. This is why blood tests of hormone levels are typically normal in PMDD and are not used to make the diagnosis.
Genetic factors also appear to play a role. Twin studies suggest heritability on the order of 30 to 50 percent, and research has identified differences in cellular sensitivity to sex hormones (including in the ESC/E(Z) gene complex) in people with PMDD. A personal history of major depression, anxiety disorders, postpartum depression, and trauma appears to raise risk. Per the Cleveland Clinic, PMDD is considered biologically distinct from depression that merely worsens premenstrually, though the two can overlap and sometimes coexist.
Symptoms
The DSM-5-TR criteria for PMDD require at least 5 symptoms during the luteal phase of most cycles, with at least one being a core affective symptom. The core affective symptoms are marked mood swings or affective lability; marked irritability, anger, or increased interpersonal conflict; marked depressed mood, hopelessness, or self-deprecating thoughts; and marked anxiety, tension, or feeling on edge.
Additional symptoms include decreased interest in usual activities, difficulty concentrating, fatigue or low energy, appetite changes or food cravings, sleep disturbance (insomnia or sleeping too much), a sense of being overwhelmed or out of control, and physical symptoms (breast tenderness, joint or muscle pain, bloating, or weight gain). To meet criteria, symptoms must remit within a few days after menses onset and be minimal or absent in the week after menstruation. Suicidal ideation appears to be more common in PMDD than in matched comparison groups and warrants direct, routine screening (see the safety section below).
How PMDD Is Diagnosed
Diagnosis requires prospective symptom tracking across at least two consecutive cycles using a validated tool such as the Daily Record of Severity of Problems (DRSP). Retrospective recall is unreliable because people with mood disorders often misattribute symptoms to the menstrual cycle, and a cyclic pattern can only be confirmed by charting symptoms day by day as they happen. The DRSP is freely available and asks the person to rate a standard list of symptoms each day across one to two full cycles.
A thorough evaluation should also screen for and, where present, distinguish PMDD from conditions that can mimic or coexist with it, including major depressive disorder, persistent depressive disorder, generalized anxiety disorder, bipolar disorder, premenstrual exacerbation of an underlying mood disorder (PME), thyroid dysfunction, and perimenopause-related mood symptoms. Substance use, medication side effects, and chronic medical conditions should also be considered. Because hormone levels in affected people are typically normal, hormone testing is not used to confirm or rule out PMDD. ACOG’s 2023 Clinical Practice Guideline on premenstrual disorders reinforces prospective charting as the cornerstone of an accurate diagnosis.
Treatment Options
Treatment for PMDD is individualized and prescriber-directed. What follows describes the categories of options a clinician may consider; it is not a recommendation of any specific drug, dose, or schedule for you. Do not start, stop, or adjust any medication on your own.
SSRIs (selective serotonin reuptake inhibitors) are considered first-line and have the strongest evidence base. Unlike their use in major depression, SSRIs often act rapidly in PMDD — sometimes within a day or two — likely because they influence neurosteroid metabolism in addition to serotonin signaling. Depending on the person, a prescriber may use them continuously or only during the luteal phase, with studies showing meaningful benefit from both approaches. Fluoxetine, sertraline, and paroxetine carry FDA approval for PMDD, and other SSRIs such as escitalopram are also used. Which agent, dose, and dosing pattern is appropriate is a clinical decision made with your prescriber, who will also monitor for side effects and interactions.
Hormonal options include drospirenone-containing combined oral contraceptives (for example, Yaz and Beyaz), which carry FDA approval for PMDD and can reduce symptoms by suppressing ovulation. For many people, continuous or extended-cycle dosing — minimizing or eliminating the hormone-free interval — produces better symptom control than traditional 21/7 regimens, but this too is a decision made with a clinician who weighs your medical history and risk factors. Drospirenone-containing combined contraception is generally regarded as a reasonable first-line hormonal option.
For severe, treatment-resistant PMDD, GnRH agonists with “add-back” hormone therapy can be effective by inducing a reversible, medically induced menopause; this is a specialist-supervised option because of its own risks. In rare, carefully selected cases, bilateral oophorectomy with hysterectomy is sometimes considered for severely affected people who have completed childbearing and have not responded to other treatments — a major, irreversible decision that requires careful multidisciplinary discussion. Cognitive behavioral therapy (CBT) has reasonable evidence in PMDD and is often combined with medication. Lifestyle measures that may help some people include regular aerobic exercise, calcium supplementation (commonly studied at around 1,200 mg daily), and reducing alcohol and caffeine — reasonable general steps, though they are not a substitute for evaluation when symptoms are disabling. Emerging approaches, such as deep transcranial magnetic stimulation, are being studied but are not yet established treatments.
When to See a Doctor
Schedule a visit if premenstrual symptoms significantly affect your work, relationships, or daily functioning, or if you experience suicidal thoughts during any phase of the cycle. Bringing two cycles of symptom-diary data to the appointment substantially shortens the path to an accurate diagnosis. A clinician comfortable with PMDD evaluation — typically in gynecology or psychiatry — can help match treatment to your symptom severity and pattern, and can adjust the plan over time.
People with a personal or family history of mood disorders, postpartum depression, or perimenopausal mood symptoms may benefit from raising the topic earlier. PMDD often coexists with other mental health conditions, and addressing an underlying mood or anxiety disorder alongside cyclic treatment tends to improve outcomes.
PMDD, Suicide Risk, and Getting Help Now
PMDD carries a genuinely elevated risk of suicidal thoughts and self-harm, and this deserves to be taken seriously rather than dismissed as “just PMS.” Research has consistently linked PMDD with higher rates of suicidal ideation and suicide attempts, with the risk concentrated in the luteal phase; some studies and reviews suggest people with PMDD are several times more likely to report suicidal thoughts than those without the condition. The International Association for Premenstrual Disorders (IAPMD) has highlighted this risk, and in 2025 argued that suicidality should be formally considered for inclusion in the diagnostic criteria for PMDD. These figures come from population and review studies and describe risk at a group level — they are not a prediction about any individual — but they underline why cyclic suicidal thoughts should never be brushed off.
If you are in crisis, get help right away. In the US, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7 and free; you can also chat online at 988lifeline.org. If you have suicidal thoughts with intent or a plan, thoughts of harming others, or any immediate safety concern, call 911 or go to the nearest emergency room. PMDD-related suicidal ideation is real and warrants urgent care — do not wait for the cycle to turn.
Frequently Asked Questions
How is PMDD different from PMS?
PMS involves milder physical and mood symptoms in the luteal phase and is very common. PMDD is a distinct disorder requiring at least 5 symptoms with at least one core affective symptom, marked distress or functional impairment, and confirmation against DSM-5-TR criteria through prospective charting — it affects an estimated 3 to 8 percent of menstruating people versus the much larger group with PMS.
Do SSRIs work right away for PMDD?
Often, yes — and that is a notable difference from their use in major depression. In PMDD, SSRIs frequently begin reducing symptoms within a day or two, which is part of why luteal-phase-only dosing is feasible for some people. Whether that fits your situation is a decision for your prescriber, not something to try on your own.
Can birth control make PMDD worse?
It depends on the formulation and the individual. Drospirenone-containing combined contraception is FDA-approved for PMDD and helps many people, especially with continuous dosing. Other hormonal contraceptives can sometimes worsen mood symptoms in some individuals. Tracking your response and staying in touch with your clinician is important; switching formulations or dosing patterns is sometimes needed.
Does PMDD go away after menopause?
Because PMDD depends on cyclic hormonal changes, symptoms typically resolve once menstruation stops permanently. The perimenopausal years can be especially difficult because hormonal swings are unpredictable; symptoms often improve once full menopause is reached.
Is PMDD a real medical diagnosis?
Yes. PMDD is a recognized psychiatric diagnosis in the DSM-5-TR and is addressed in ACOG’s clinical guidance on premenstrual disorders. It is a legitimate, treatable condition — not a character flaw or an exaggeration of normal premenstrual symptoms.
The bottom line: PMDD is a real, treatable, DSM-5-TR-recognized cyclic mood disorder — not a personal failing or simply a worse version of PMS. Two cycles of prospective symptom tracking distinguish it from other mood disorders and dramatically improve diagnostic accuracy. SSRIs and drospirenone-containing combined contraceptives are first-line, but the choice of treatment, dose, and schedule belongs to you and your prescriber — never self-dose. Because PMDD carries an elevated risk of suicidal thoughts, take any crisis seriously: in the US, call or text 988 for the Suicide & Crisis Lifeline. This article is for general education only and is not a substitute for care from a qualified clinician.
Sources
- American College of Obstetricians and Gynecologists (ACOG) — Premenstrual Syndrome (PMS) FAQ; Clinical Practice Guideline No. 7, Management of Premenstrual Disorders (2023)
- American Psychiatric Association — Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR, 2022)
- International Association for Premenstrual Disorders (IAPMD) — Facts & Figures; Self-Harm & Suicidality resources
- Cleveland Clinic — Premenstrual Dysphoric Disorder (PMDD)
- 988 Suicide & Crisis Lifeline (988lifeline.org)